Peter Koelblinger

805 total citations
35 papers, 470 citations indexed

About

Peter Koelblinger is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Peter Koelblinger has authored 35 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Peter Koelblinger's work include Cutaneous Melanoma Detection and Management (16 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Peter Koelblinger is often cited by papers focused on Cutaneous Melanoma Detection and Management (16 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Peter Koelblinger collaborates with scholars based in Austria, Switzerland and Germany. Peter Koelblinger's co-authors include Reinhard Dummer, Thuerigen Olaf, Roland Lang, Michael Emberger, Phil F. Cheng, Barbara Seliger, Diana Handke, Joanna Mangana, Johann Bauer and Anja Müeller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Peter Koelblinger

33 papers receiving 463 citations

Peers

Peter Koelblinger
Michelle S. Miller United States
Malini Guha Canada
Janice M. Mehnert United States
Jessica Merulla Switzerland
Krysta Schlis United States
Eleanor Dagostino United States
Moacyr Oliveira United States
Robert H. Sinnamon United States
Mary Luz Uribe Spain
Michelle S. Miller United States
Peter Koelblinger
Citations per year, relative to Peter Koelblinger Peter Koelblinger (= 1×) peers Michelle S. Miller

Countries citing papers authored by Peter Koelblinger

Since Specialization
Citations

This map shows the geographic impact of Peter Koelblinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Koelblinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Koelblinger more than expected).

Fields of papers citing papers by Peter Koelblinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Koelblinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Koelblinger. The network helps show where Peter Koelblinger may publish in the future.

Co-authorship network of co-authors of Peter Koelblinger

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Koelblinger. A scholar is included among the top collaborators of Peter Koelblinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Koelblinger. Peter Koelblinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Long, Georgina V., Paolo A. Ascierto, Jun Guo, et al.. (2025). Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.. Journal of Clinical Oncology. 43(17_suppl). 2 indexed citations
2.
Otto, Ferdinand, Lara Bieler, Tobias Moser, et al.. (2024). Beyond T cell toxicity – Intrathecal chemokine CXCL13 indicating B cell involvement in immune‐related adverse events following checkpoint inhibition: A two‐case series and literature review. European Journal of Neurology. 31(7). e16279–e16279. 7 indexed citations
3.
Höeller, Christoph, Lukas Koch, Erika Richtig, et al.. (2024). Immune checkpoint inhibitor‐induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy—A multicentre analysis. Journal of the European Academy of Dermatology and Venereology. 39(9). 1656–1665.
4.
Ayati, Narjess, et al.. (2023). Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2715–2726. 3 indexed citations
5.
Lang, Roland, Erika Richtig, Ingrid Wolf, et al.. (2023). Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies. Journal of the European Academy of Dermatology and Venereology. 37(9). 1799–1810. 11 indexed citations
6.
7.
8.
Forchhammer, Stephan, Laura Del Regno, Georg Lodde, et al.. (2023). The impact of the COVID‐19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. Journal of the European Academy of Dermatology and Venereology. 37(5). 922–931. 8 indexed citations
9.
Koelblinger, Peter, et al.. (2023). Immunotherapy for metastatic melanoma—from little benefit to first-line treatment. memo - Magazine of European Medical Oncology. 16(2). 108–112.
10.
Weber, Daniela D., Sepideh Aminzadeh-Gohari, Luca Catalano, et al.. (2022). Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity. SHILAP Revista de lepidopterología. 10(1). 12–12. 22 indexed citations
11.
Lang, Roland, Peter Koelblinger, Erika Richtig, et al.. (2022). Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).. Journal of Clinical Oncology. 40(16_suppl). 9528–9528. 2 indexed citations
12.
Koch, Lukas, Joanna Mangana, Sofiya Latifyan, et al.. (2021). Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. Journal for ImmunoTherapy of Cancer. 9(2). e001701–e001701. 38 indexed citations
13.
Koelblinger, Peter, Lukas Koch, Erika Richtig, et al.. (2021). Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 19(8). 1186–1198. 4 indexed citations
14.
Koelblinger, Peter, Lukas Koch, Erika Richtig, et al.. (2021). Adjuvante Anti‐PD‐1‐Antikörpertherapie bei Stadium‐III/IV‐Melanom: Anwendungsdaten aus der klinischen Routine und gesundheitsökonomische Aspekte. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 19(8). 1186–1200. 1 indexed citations
15.
Kempf, Werner, Joanna Mangana, Phil F. Cheng, et al.. (2020). The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma. Histopathology. 77(3). 460–470. 16 indexed citations
16.
Massa, Chiara, Michael Friedrich, Diana Handke, et al.. (2020). Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. OncoImmunology. 9(1). 1774323–1774323. 29 indexed citations
17.
Höeller, Christoph, Lukas Koch, Peter Koelblinger, et al.. (2019). Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland. Annals of Oncology. 30. v548–v549. 2 indexed citations
18.
Koelblinger, Peter & Roland Lang. (2018). New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. OncoTargets and Therapy. Volume 11. 8327–8340. 21 indexed citations
19.
Koelblinger, Peter, et al.. (2017). A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncology. 13(20). 1755–1766. 40 indexed citations
20.
Koelblinger, Peter, Thuerigen Olaf, & Reinhard Dummer. (2017). Development of encorafenib for BRAF-mutated advanced melanoma. Current Opinion in Oncology. 30(2). 125–133. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle S. Miller Breakdown of academic impact, for papers by Malini Guha Breakdown of academic impact, for papers by Janice M. Mehnert Breakdown of academic impact, for papers by Jessica Merulla Breakdown of academic impact, for papers by Krysta Schlis Breakdown of academic impact, for papers by Eleanor Dagostino Breakdown of academic impact, for papers by Moacyr Oliveira Breakdown of academic impact, for papers by Robert H. Sinnamon Breakdown of academic impact, for papers by Mary Luz Uribe
Rankless by CCL
2026